Patent Application
20160200751
The present invention relates to organic chemical and medicinal chemical area. More specifically, the present invention relates to thienopiperidine derivative and pharmaceutically acceptable acid addition salt thereof, the present invention also relates to the method for preparation of thienopiperidine derivative and the uses of the thienopiperidine derivative and pharmaceutically acceptable acid addition salt thereof in preparing drugs for preventing platelet aggregation and for treating and preventing cardiovascular and cerebrovascular diseases.
Clopidogrel is one kind of thienopiperidine derivative medicine, which could efficiently inhibit the platelet activity, is one anti-platelet medicine widely used for acute coronary syndrome and patients treated with percutaneous coronary intervention, with the following structural formula:
Clopidogrel is one kind of prodrug with no activity, which needs to be converted into active metabolite by liver cytochrome P450 (CYP450), the metabolic process of which is as follows:
The metabolite binds with adenosine diphosphate (ADP) receptor P2Y12 on platelet membrane surface, playing a role of blocking the binding of ADP and platelet receptor and secondary ADP-mediated glycoprotein GPIIbPIIIa complex activation, and then inhibiting platelet aggregation (Arterioscler. Thromb. Vase. Biol., 1999, 19 (8): 2002-2011). Clopidogrel can significantly lower the occurrence rate of subacute stent thrombosis, decrease the occurrence of death, recurrent myocardial infarction and other cardiovascular events. However, recent research has found that about 11%˜44% (Am. Heart J., 2009, 157(2): 375-382) patients show low response even no response to clopidogrel, which is defined as clopidogrel resistance.
Therefore, there's a need to develop a new antiplatelet drug which has fast action, high efficacy and can avoid clopidogrel resistance on clinic. Meanwhile, finding a compound which is favorable for preparation, in order to improve bioavailability, reduce side effect, and be favorable for dissolution, absorption and administration.
The object of the present invention is to provide a new thienopiperidine derivative which acts as a prodrug of clopidogrel metabolite 2-oxo clopidogrel, to develop an antiplatelet drug with fast action and high bioavailability.
More specially, one object of the present invention is to provide an optical active thienopiperidine derivative or pharmaceutically acceptable salt thereof
Another object of the present invention is to provide a pharmaceutical composition with the optical active thienopiperidine derivative or pharmaceutically acceptable, salt thereof as active constituents.
Another object of the present invention is to provide a method for preparation of the optical active thienopiperidine derivative or pharmaceutically acceptable salt thereof.
Another object of the present invention is to provide the uses of the optical active thienopiperidine derivative or pharmaceutically acceptable salt thereof or pharmaceutical composition comprising these compounds in preparing drugs for preventing platelet aggregation.
Another object of the present invention is to provide the methods using the optical active thienopiperidine derivative or pharmaceutically acceptable salt thereof or pharmaceutical composition comprising these compounds in preventing platelet aggregation.
Another object of the present invention is to provide the uses of the optical active thienopiperidine derivative or pharmaceutically acceptable salt thereof or pharmaceutical composition comprising these compounds in preparing drugs for preventing or treating cardiovascular and cerebrovascular diseases.
Another object of the present invention is to provide the methods using the optical active thienopiperidine derivative or pharmaceutically acceptable salt thereof or pharmaceutical composition comprising these compounds in preventing or treating cardiovascular and cerebrovascular diseases.
That is, the present application includes the following invention:
1. A thienopiperidine derivative of a general formula (I) or pharmaceutically acceptable acid addition salts thereof:
Wherein,
represents —O—R or ═O; X is P or S; m is 0 or 1; R, R′ can be the same or different, respectively and independently are H, C1-C4 straight or branched alkyl substituted by halogen or unsubstituted, phenyl or substituted phenyl.
2. The thienopiperidine derivative or pharmaceutically acceptable acid addition salts thereof according to paragraph 1, wherein the thienopiperidine derivative of a general formula formula (II) or formula (III):
Wherein, X is P or S; m is 0 or 1; n is 0 or 1; R, R′ is the same or different, respectively and independently are H, C1-C4 braight or branched alkyl substituted by halogen or unsubstituted, phenyl or substituted phenyl.
3. The thienopiperidine derivative or pharmaceutically acceptable acid addition salts thereof according to paragraph 1 or 2, wherein, X is P; m is 0; n is 0; R, R′ is the same or different, respectively and independently are H, CH3—, CH3CH2—, propyl, CCl3CH2— or phenyl.
4. The thienopiperidine derivative or pharmaceutically acceptable acid addition salts thereof according to paragraph 3, wherein, the propyl is isopropyl.
5. The thienopiperidine derivative or pharmaceutically acceptable acid addition salts thereof according to paragraph 1 or 2, wherein, X is P; m is 1; n is 1; R, R′ is the same or different, respectively and independently are H, CH3—, CH3CH2—, propyl, CCl3CH2—, butyl or phenyl.
6. The thienopiperidine derivative or pharmaceutically acceptable acid addition salts thereof according to paragraph 1 or 2, wherein, X is S; m is 0; n is 0; R, R′ is the same or different, respectively and independently are H, CH3—, CH3CH2—, propyl, CCl3CH2—, butyl or phenyl.
7. The thienopiperidine derivative or pharmaceutically acceptable acid addition salts thereof according to paragraph 5 or 6, wherein, the propyl is isopropyl, the butyl is tert-butyl.
8. The thienopiperidine derivative or pharmaceutically acceptable acid addition salts thereof according to paragraph 1, wherein, the thienopiperidine derivative is selected from the group consisting of:
9. The thienopiperidine derivative or pharmaceutically acceptable acid addition salts thereof according to any one of paragraph 1-8, wherein said acceptable acid addition salts are prepared by reacting the thienopiperidine derivative with the following acids: sulphuric acid, muriatic acid, hydrobromic acid, phosphoric acid, tartaric acid, fumaric acid, maleic acid, citric acid, acetic acid, formic acid, methanesulfonic acid, p-toluene sulfonic acid, oxalic acid or succinic acid.
10. A pharmaceutical composition containing the thienopiperidine derivative according to any one of paragraph 1-9 or its pharmaceutically acceptable acid addition salts.
11. The pharmaceutical composition according to paragraph 10, wherein said composition further contains pharmaceutically acceptable carrier(s).
12. A use of any thienopiperidine derivative or pharmaceutically acceptable acid addition salts thereof according to any one of paragraph 1-9 or the pharmaceutical composition according to paragraph 10 or 11 in preparing drugs for preventing platelet aggregation.
13. A use of the thienopiperidine derivative or pharmaceutically acceptable acid addition salts thereof according to any one of the paragraph 1-9 or the pharmaceutical composition according to paragraph 10 or 11 in preparing drugs for treating or preventing cardiovascular and cerebrovascular diseases.
14. The uses according to paragraph 13, wherein said cardiovascular and cerebrovascular diseases are one or more of heart failure, apoplexy and unstable angina.
15. A method for preventing platelet aggregation, which includes administering the thienopiperidine derivative or pharmaceutically acceptable acid addition salts thereof according to any one of paragraph 1-9 or the pharmaceutical composition according to paragraph 10 or 11 to the subjects.
16. A method for preventing or treating cardiovascular and cerebrovascular diseases, which includes administering the thienopiperidine derivative or pharmaceutically acceptable acid addition salts thereof according to any one of paragraph 1-9 or the pharmaceutical composition according to paragraph 10 or 11 to the subjects.
To achieve the above objects, the present invention adopts the following technical scheme:
The present invention provides a optical active thienopiperidine derivative of a formula (I) and pharmaceutically acceptable salts thereof or a pharmaceutical composition comprising the above compounds as active constituents:
In formula (I),
can be —O—R or ═O, that is, the compounds according to formula (I) in the present invention can be represented by formula (II) or formula (III):
In formula (I) to formula (III),
X is P or S; m is 0 or 1; n is 0 or 1; R, R′ can be the same or different, respectively and independently are H, C1-C4 braight or branched alkyl substituted by halogen or unsubstituted, phenyl or substituted phenyl.
Preferably, X is P; m is 0; n is 0; R, R′ can be the same or different, respectively and independently are H, CH3—, CH3CH2—, propyl, CCl3CH2— or phenyl; more preferably, the propyl is isopropyl.
Or, preferably, X is P; m is 1; n is 1; R, R′ can be the same or different, respectively and independently are H, CH3—, CH3CH2—, propyl, CCl3CH2—, butyl or phenyl; more preferably, the propyl is isopropyl, the butyl is tert-butyl.
Or preferably, X is S; m is 0; n is 0; R is H, CH3—, CH3CH2—, propyl, CCl3CH2—, butyl or phenyl; more preferably, the propyl is isopropyl, the butyl is tert-butyl.
Most preferably, the thienopiperidine derivatives of the present invention are represented by the following compounds:
As another side of the invention, pharmaceutically acceptable acid addition salts of the thienopiperidine derivative are also included, wherein said acceptable acid addition salts are prepared by reacting the thienopiperidine derivative with the following organic acid or inorganic acid: sulphuric acid, muriatic acid, hydrobromic acid, phosphoric acid, tartaric acid, fumaric acid, maleic acid, citric acid, acetic acid, formic acid, methanesulfonic acid, p-toluene sulfonic acid, oxalic acid or succinic acid and so on.
As another side of the present invention, it also provides a method for preparing thienopiperidine derivative or pharmaceutically acceptable acid addition salts thereof.
For example, for the thienopiperidine derivative according to formula (II) of the present invention, the preparation methods are as follows:
While m=0, n=0,
While m=1, n=1:
Wherein, the definition of the substituents is as mentioned above.
For the thienopiperidine derivative according to formula (III) in the present invention, its preparation methods are as follows:
While m=0, n=0:
While m=1, n=1:
Wherein, the definition of the substituents is as mentioned above. Besides, the formula VI can also be replaced by sodium salts.
More specially, according to the detailed description of the present invention, the compound TSC-9 can be prepared by the following method:
Wherein, R is chlorine or hydroxyl.
The method for preparing the material compound according to formula (IV) can refer to literature Journal of Medicinal Chemistry, 2012, 55(7), 3342-3352.
As another side of the present invention, it also provides a pharmaceutical composition, wherein said composition comprises the thienopiperidine derivative or pharmaceutically acceptable acid addition salts thereof as active constituents. As required, the pharmaceutical composition can also comprise pharmaceutically acceptable carrier(s). The pharmaceutically acceptable carrier(s) can be solid or liquid.
The pharmaceutical composition of the present invention can be made into solid or semisolid pharmaceutical preparations in the form of powder (like dispersible powder), tablet, capsule, suppository, plaster, gelata and so on, in this case, solid carriers are usually used. The solid carriers are preferably chosen from one or more of diluent, flavoring agent, solubilizer, lubricant, suspension concentrate, adhesive, expander, pharmacoat and so on. In powder preparation, the carrier contains 5 wt %-70 wt % of micronized active constituents. The instantiations of suitble solid carriers include magnesium carbonate, magnesium stearate, talc, sucrose, lactose, pectin, dextrine, starch, gelatin, tragacanth gum, methyl cellulose, carboxymethylcellulose sodium, low boiling wax, cacao butter and so on. The solid or semisolid pharmaceutical preparation is easy for drug administration, so it's a preferrable preparation form, especially the solid preparation represented by tablet, powder, capsule are the oral solid preparation mostly favorable to be absorbed.
Besides, the pharmaceutical composition of the present invention can also be made into liquid preparation. The liquid preparation includes solution, injection, suspension concentrate and emulsion. For example, injection for non parenteral administration can be made in the form of aqueous solution, propylene glycol aqueous solution or polyethylene glycol aqueous solution, the injection's isotonic concentration, pH and so on are adjusted, making it suitable for the physiological condition of the living body. For another example, the above active constituents can be dissolved in the water, and then suitble colorant, flavoring agent, stabilizer and thickener are added, to prepare oral solution; or, the micronized active constituents can be dispersed in the goop(like natural or synthetic rubber), methyl cellulose, carboxymethylcellulose sodium and other known suspending medium, to prepare oral suspension concentrate.
For easy drug administration and uniform dosage, it's very favorable to prepare the above pharmaceutical preparation in dosage unit form. The dosage unit form is a physical sepration unit suitable to be a single dosage, each unit contains predetermined amount of active constituents producing the desired therapeutic effect. The dosage unit form can be in the form of package, like tablet, capsule or powder in small tubules or bottles, or ointment, gelata or cream in tubules or bottles.
Although the amount of the active constituents in each dosage unit form can be changed, it's usually regulated in the range of 1-1000mg, according to the effectiveness of the chosen active constituents.
A person skilled in the art can determine the preferable dosage suitable for some situation according to the regular methods. Generally speaking, the dosage at the beginning of treatment is lower than the optimal dosage of the active constituents, and then the drug administration dosage is increased gradually, until the best therapeutic effect is achieved. For convenience, the total daily dosage can be divided into several parts, several times to administer drugs.
As another side of the present invention, the present invention relates to the uses of the thienopiperidine derivative or pharmaceutically acceptable acid addition salt thereof in preparing drugs for treating or preventing cardiovascular and cerebrovascular diseases including heart failure, apoplexy, unstable angina and so on, especially the uses in preparing drugs for preventing platelet aggregation.
The beneficial effects of the present invention is that, the present invention provides a new kind of compound preventing platelet aggregation obviously, which is the prodrug of clopidogrel metabolite 2-oxo clopidogrel, can be metabolized into 2-oxo clopidogrel without CYP2C19 enzyme in vivo, having fast action, high efficacy, besides, the present invention is hoped to solve the problem of clopidogrel resistance due to the expression difference of P450 (cytochrome P450, CYP) enzyme in different individuals.
The below, further explains the present invention according to examples, but not as a limit for the present invention.
2-oxo clopidogrel intermediate IV (200 mg, 0.6 mmol) was dissolved in 5 ml anhydrous tetrahydrofuran, cooled to minus 20 degrees, lithium diisopropylamide (2.0M, 0.5 ml, 1 mmol) was added and stirred for 20 minutes, compound Va (104 mg, 0.72 mmol) was added into the reaction solution, rised naturally to room temperature to react for 12 hours, quenched by 4% hydrochloric acid, 50 ml ethyl acetate was added, the organic layer was washed by sodium bicarbonate and saturated salt water respectively, dried with anhydrous sodium sulfate, filtrated and concentrated. After purification by silica gel column chromatograph (petroleum ether:ethyl acetate (PE:EA)=4:1), compound TSC-1 (245 mg, yield 92%) was obtained.
1H NMR(400 MHz, CDCl3): δ 7.67-7.65 (m, 1H), 7.42-7.40 (m, 1H), 7.31-7.26 (m, 2H), 6.25 (d, 1H), 4.91 (s, 1H), 3.87 (s, 3H), 3.72 (s, 3H), 3.64-3.60 (m, 1H), 3.51-3.48 (m, 1H), 2.89-2.87 (m, 2H), 2.75-2.73 (m, 2H), MS: m/z 446 [M+1]+.
Preparation example 2
2-oxo clopidogrel intermediate IV (500 mg, 1.5 mmol) was dissolved in 10 ml anhydrous tetrahydrofuran, cooled to minus 20 degrees, lithium diisopropylamide (2.0M, 1.25 ml, 2.5 mmol) was added and stirred for 30 minutes, compound Vb (311 mg, 1.8 mmol) was added into the reaction solution, rised naturally to room temperature to react for 12 hours, quenched by 4% hydrochloric acid, 100 ml ethyl acetate was added, the organic layer was washed by sodium bicarbonate and saturated salt water respectively, dried with anhydrous sodium sulfate, filtrated and concentrated. After purification by silica gel column chromatograph (PE:EA=4:1), compound TSC-2 (660 mg, yield 93%) was obtained.
1H NMR(400 MHz, CDCl3): δ 7.69-7.66 (m, 1H), 7.43-7.41 (m, 1H), 7.33-7.28 (m, 2H), 6.27 (d, 1H), 4.91 (s, 1H), 4.27-4.18 (m, 4H), 3.73 (s, 3H), 3.65-3.61 (m, 1H), 3.52-3.49 (m, 1H), 2.90-2.87 (m, 2H), 2.76-2.74 (m, 2H), 1.39-1.36 (dt, 6H). MS: mlz 474 [M+1]+.
Preparation example 3
2-oxo clopidogrel intermediate IV (150 mg, 0.45 mmol) was dissolved in 5 ml anhydrous tetrahydrofuran, cooled to minus 20 degrees, lithium diisopropylamide (2.0M, 0.4 ml, 0.8 mmol) was added and stirred for 20 minutes, compound Vc (108 mg, 0.54 mmol) was added into the reaction solution, rised naturally to room temperature to react for 12 hours, quenched by 4% hydrochloric acid, 50 ml ethyl acetate was added, the organic layer was washed by sodium bicarbonate and saturated salt water respectively, dried with anhydrous sodium sulfate, filtrated and concentrated. After purification by silica gel column chromatograph (PE:EA=2:1), compound TSC-3 (192 mg, yield 85%) was obtained.
1H NMR(400 MHz, CDCl3): δ 7.68-7.67 (m, 1H), 7.41-7.39 (m, 1H), 7.34-7.28 (m, 2H), 6.28 (d, 1H), 4.92 (s, 1H), 4.74 (m, 2H), 4.26-4.17 (m, 4H), 3.73 (s, 3H), 3.64-3.61 (m, 1H), 3.53-3.49 (m, 1H),1.28 (d, 12H). MS:m/z 502 [M+1]+.
Preparation example 4
2-oxo clopidogrel intermediate IV (100 mg, 0.3 mmol) was dissolved in 5 ml anhydrous tetrahydrofuran, cooled to minus 20 degrees, lithium diisopropylamide (2.0M, 0.25 ml, 0.5 mmol) was added and stirred for 20 minutes, compound Vd (97 mg, 0.36 mmol) was added into the reaction solution, rised naturally to room temperature to react for 12 hours, quenched by 4% hydrochloric acid, 50 ml ethyl acetate was added, the organic layer was washed by sodium bicarbonate and saturated salt water respectively, dried with anhydrous sodium sulfate, filtrated and concentrated. After purification by silica gel column chromatograph (PE:EA=2:1), compound TSC-4 (162 mg, yield 95%) was obtained.
1H NMR(400 MHz, CDCl3): δ 7.71-7.68 (m, 1H), 7.47-7.42 (m, 5H), 7.35-7.24 (m, 10H), 6.28 (d, 1H), 4.92 (s, 1H), 3.64-3.60 (m, 1H), 3.51-3.48 (m, 1H), 2.89-2.87 (m, 2H), 2.75-2.73 (m, 2H), MS: m/z 570 [M+1]+.
Preparation example 5
2-oxo clopidogrel intermediate IV (300 mg, 0.9 mmol) was dissolved in 15 ml anhydrous tetrahydrofuran, cooled to minus 20 degrees, lithium diisopropylamide (2.0M, 0.75 ml, 1.5 mmol) was added and stirred for 20 minutes, compound Ve (493 mg, 1.3 mmol) was added into the reaction solution, rised naturally to room temperature to react for 12 hours, quenched by 4% hydrochloric acid, 200 ml ethyl acetate was added, the organic layer was washed by sodium bicarbonate and saturated salt water respectively, dried with anhydrous sodium sulfate, filtrated and concentrated. After purification by silica gel column chromatograph (PE:EA=3:1), compound TSC-5 (400 mg, yield 65%) was obtained.
1H NMR(400 MHz, CDCl3): δ 7.68-7.67 (m, 1H), 7.41-7.39 (m, 1H), 7.34-7.28 (m, 2H), 6.28 (d, 1H), 4.92 (s, 1H), 4.26-4.17 (m, 4H), 3.73 (s, 3H), 3.64-3.61 (m, 1H), 3.53-3.49 (m, 1H), 2.92-2.88 (m, 2H), 2.76-2.75 (m, 2H). MS: m/z 678 [M+1]+.
Preparation example 6
TSC-2 (500 mg, 1.04 mmol) was dissolved in 10 ml dry dichloromethane, TMSBr (1.7 ml, 13 mmol was added, reacted at room temperature for 12h, the reaction was stopped, the solvent was removed under reduced pressure, 10 ml methanol was added and stirred for 1 h. The reaction solution was concentrated directly, purified by silica gel column chromatograph (n-butanol:formic acid:water=5:5:1), compound TSC-6 (390 mg, yield 90%) was obtained.
1H NMR(400 MHz, DMSO): δ 7.60 (d, 1H), 7.53 (d, 1H), 7.41-7.40 (m, 2H), 6.24 (s, 1H), 4.91 (s, 1H), 3.67 (s, 3H), 3.56 (s, 2H), 2.85 (brs, 2H), 2.66 (brs, 2H), MS: m/z 418 [M+1]+.
Preparation example 7
2-oxo clopidogrel intermediate IV (500 mg, 1.5 mmol) was dissolved in 5 ml anhydrous tetrahydrofuran, cooled to minus 20 degrees, lithium diisopropylamide (2.0M, 1.25 ml, 2.5 mmol) was added and stirred for 20 minutes, compound Vf (466 mg, 1.8 mmol) was added into the reaction solution, rised naturally to room temperature to react for 12 hours, quenched by 4% hydrochloric acid, 100 ml ethyl acetate was added, the organic layer was washed by sodium bicarbonate and saturated salt water respectively, dried with anhydrous sodium sulfate, filtrated and concentrated. After purification by silica gel column chromatograph (PE:EA=2:1), compound TSC-7 (269 mg, yield 32%) was obtained.
1H NMR(400 MHz, CDCl3): δ 7.69-7.65 (m, 1H), 7.42-7.40 (m, 1H), 7.31-7.24 (m, 2H), 6.17 (s, 1H), 5.46 (s, 1H), 5.43 (s, 1H), 4.91 (s, 1H), 3.73 (s, 3H), 3.64-3.60 (m, 1H), 3.50-3.47 (m, 1H), 2.91-2.88 (m, 2H), 2.75-2.72 (m, 2H), 1.50 (s, 18H). MS: m/z 560 [M+1]+.
Preparation example 8
TSC-6 (500 mg, 0.89 mmol) was dissolved in 10 ml dichloromethane, trifluoroacetic acid (2 ml) was added, stirred at room temperature for 1 h, concentrated under reduced pressure, purified by silica gel column chromatograph (n-butanol:formic acid:water=5:5:1), compound TSC-8 (140 mg, yield 35%) was obtained.
1H NMR(400 MHz, DMSO): δ 7.62-7.60 (m, 1H), 7.54-7.41 (m, 3H), 6.18 (s, 1H), 5.84 (s, 1H), 5.37-5.32 (d, 2H), 4.26-3.98 (m, 2H), 3.79 (s, 3H), 3.74-3.66 (m, 2H), 3.15-3.00 (m, 2H), MS: m/z 448 [M+1]+.
Preparation example 9
2-oxo clopidogrel intermediate IV (500 mg, 1.5 mmol) was dissolved in 5 ml anhydrous tetrahydrofuran, cooled to minus 20 degrees, lithium diisopropylamide(LDA, 2.0M, 1.25 ml, 2.5 mmol) was added and stirred for 20 minutes, compound VI was added into the reaction liquid, rised naturally to room temperature to react for 12 hours, quenched by 4% hydrochloric acid, 100 ml ethyl acetate was added, the organic layer was washed by sodium bicarbonate and saturated salt water respectively, dried with anhydrous sodium sulfate, filtrated and concentrated. After purification by silica gel column chromatograph (PE:EA=2:1), compound TSC-9 (269 mg, yield 32%) was obtained.
1H NMR(400 MHz, CDCl3): δ 7.59 (s, 1H), 7.39-7.37 (m, 1H), 7.27-7.26 (d, 2H), 6.50 (brs, 1H), 6.34 (s, 1H), 4.97 (s, 1H), 3.68-3.58 (m, 5H), 2.90-2.73 (m, 4H); MS: m/z 418 [M+1]+.
A small dosage of ADP (with a concentration less than 0.9 μmol/l) was added in the platelet suspension, which could cause platelet aggregation quickly, but then deaggregation; if a medium dosage of ADP (about 1.0 μmol/l) was added, a second irreversible condensed phase appeared after the first condensed phase ended and soon after the deaggregation. The maximum aggregation rate of irreversible condensed phase can be used to evaluate the effect of subject products on coagulation function. The experiment used NJ4 type Semi-Platelet Aggregation Analyzer of precil company, to survey the inhibitory effect of the subject products provided by Tasly Holding Group. Co. Ltd on platelet aggregation.
Animal grouping: the experimental rats were divided randomly according to body weight into negative control group, clopidogrel group, prasugrel group, vicagrel group, TSC-lgroup, TSC-2 group, TSC-3 group, TSC-4 group, TSC-5 group, TSC-6 group, TSC-7group, TSC-8 group and TSC-9 group, the number of rats n in each group was showed in table 1.
2 hours after administering drugs to the rats, anesthesia with mebubarbital, draw blood from abdominal aorta, anticoagulation with sodium citrate 1:9. Obtained platelet-rich plasma and platelet-poor plasma by centrifugation, the volume ratio of the two was platelet-poor plasma :platelet-rich plasma=3:1.
In the experiment of platelet aggregation induced by ADP, each subject product has the effect of obviously inhibiting the platelet aggregation, and can reverse the platelet second phase aggregation, causing deaggregation. So, the thienopiperidine derivative and pharmaceutically acceptable salt thereof in the present invention can be effectively used for preventing platelet aggregation.
Platelet is a key constituent in the normal clotting mechanism, and also is an important cause forming pathological thrombus, platelet aggregation is the initiating factor forming intra arterial thrombus, playing a key role in initiation of cardiovascular and cerebrovascular diseases (such as heart failure, apoplexy, unstable angina and so on). The chance of occurrence of cardiovascular and cerebrovascular diseases is reduced, while the probably of thrombosis is reduced by inhibiting platelet aggregation. Therefore, inhibiting platelet aggregation has close correlation with preventing or treating cardiovascular and cerebrovascular diseases.
Therefore, as the thienopiperidine derivative and pharmaceutically acceptable salt thereof in the present invention can be effectively used for inhibiting platelet aggregation, it can be effectively used for preventing or treating various diseases caused by platelet aggregation, including by not limited by cardiovascular and cerebrovascular diseases, such as heart failure, apoplexy, unstable angina and so on.
| Number | Date | Country | Kind |
|---|---|---|---|
| 201310428052.4 | Sep 2013 | CN | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CN2014/086191 | 9/10/2014 | WO | 00 |
